These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9816012)
41. Relations of proliferative activities of gastric carcinoma cells to lymphatic involvement, venous invasion and prognosis. Wu YF; Xu HM; Chen JQ Chin Med J (Engl); 2004 Oct; 117(10):1530-5. PubMed ID: 15498378 [TBL] [Abstract][Full Text] [Related]
42. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790 [TBL] [Abstract][Full Text] [Related]
43. In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region. Kotelnikov VM; Coon JS; Taylor S; Hutchinson J; Panje W; Caldarelli DD; LaFollette S; Preisler HD Cell Prolif; 1995 Sep; 28(9):497-509. PubMed ID: 7578599 [TBL] [Abstract][Full Text] [Related]
44. Heterogeneous cell kinetics in tumors analyzed with a simulation model for bromodeoxyuridine single and multiple labeling. Baisch H; Otto U; Hatje U; Fack H Cytometry; 1995 Sep; 21(1):52-61. PubMed ID: 8529471 [TBL] [Abstract][Full Text] [Related]
45. Correlation between iododeoxyuridine and MIB-1 labelling index in gastric carcinoma and adjacent normal gastric tissue. Schipper DL; Wagenmans MJ; Peters WH; Wobbes T; Wagener DJ Anticancer Res; 2000; 20(2A):707-14. PubMed ID: 10810344 [TBL] [Abstract][Full Text] [Related]
46. Influence of sampling time on assessment of potential doubling time. Høyer M; Bentzen SM; Salling LN; Overgaard J Cytometry; 1994 Jun; 16(2):144-51. PubMed ID: 7924683 [TBL] [Abstract][Full Text] [Related]
47. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Haddad RI; Weinstein LJ; Wieczorek TJ; Bhattacharya N; Raftopoulos H; Oster MW; Zhang X; Latham VM; Costello R; Faucher J; DeRosa C; Yule M; Miller LP; Loda M; Posner MR; Shapiro GI Clin Cancer Res; 2004 Jul; 10(14):4680-7. PubMed ID: 15269140 [TBL] [Abstract][Full Text] [Related]
48. [The role of p53 tumor suppressor gene as prognostic factor in laryngeal squamous cell carcinoma]. Garozzo A; Cutrona D; Palmeri S; Maiolino L; Puzzo L; Allegra E Acta Otorhinolaryngol Ital; 1999 Dec; 19(6):342-7. PubMed ID: 10875157 [TBL] [Abstract][Full Text] [Related]
49. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652 [TBL] [Abstract][Full Text] [Related]
50. RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age. Olasz J; Juhász A; Remenár E; Engi H; Bak M; Csuka O; Kásler M Oncol Rep; 2007 Jul; 18(1):105-12. PubMed ID: 17549354 [TBL] [Abstract][Full Text] [Related]
51. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653 [TBL] [Abstract][Full Text] [Related]
53. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Patel V; Lahusen T; Sy T; Sausville EA; Gutkind JS; Senderowicz AM Cancer Res; 2002 Mar; 62(5):1401-9. PubMed ID: 11888912 [TBL] [Abstract][Full Text] [Related]
54. Flow cytometry after bromodeoxyuridine labeling to measure S and G2+M phase durations plus doubling times in vitro and in vivo. Terry NH; White RA Nat Protoc; 2006; 1(2):859-69. PubMed ID: 17406318 [TBL] [Abstract][Full Text] [Related]
55. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. Weiner MF; Miranda RN; Bardales RH; Mukunyadzi P; Baker SJ; Korourian S; De Las Casas LE Diagn Cytopathol; 2004 Nov; 31(5):294-9. PubMed ID: 15468132 [TBL] [Abstract][Full Text] [Related]
56. Polymer chemotherapy for head and neck cancer. Shikani AH; Domb AJ Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503 [TBL] [Abstract][Full Text] [Related]
57. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells. Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740 [TBL] [Abstract][Full Text] [Related]
58. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy. Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R Anticancer Res; 2006; 26(2A):1091-5. PubMed ID: 16619511 [TBL] [Abstract][Full Text] [Related]
59. Comparison of two double labeling techniques to measure cell cycle kinetics in myeloid leukemias. Yousuf N; Yanik GA; George BA; Masterson M; Mazewski CM; White LM; Miller MA; Lampkin BC; Raza A Anticancer Res; 1991; 11(3):1195-9. PubMed ID: 1888149 [TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma. Nagi C; Xiao GQ; Li G; Genden E; Burstein DE Ann Diagn Pathol; 2007 Dec; 11(6):402-6. PubMed ID: 18022123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]